Do analysts rate ENGN or DTSS?

enGene presently has a consensus target price of $11.05, indicating a potential upside of 538.47%. Given enGene's stronger consensus rating and higher possible upside, research analysts clearly believe enGene is more favorable than Datasea. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14 Datasea 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ENGN or DTSS?

Datasea has higher revenue and earnings than enGene. Datasea is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Datasea $71.62M 0.11 -$5.09M -$0.32 N/A

Is ENGN or DTSS more profitable?

enGene has a net margin of 0.00% compared to Datasea's net margin of -4.80%. enGene's return on equity of -56.06% beat Datasea's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Datasea -4.80% -88.98% -37.33%

Is CTNM or ENGN more profitable?

Contineum Therapeutics' return on equity of -27.09% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% enGene N/A -56.06% -45.64%

Does the media refer more to CTNM or ENGN?

In the previous week, enGene had 9 more articles in the media than Contineum Therapeutics. MarketBeat recorded 13 mentions for enGene and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.62 beat enGene's score of 0.21 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ENGN or EOLS?

Evolus has higher revenue and earnings than enGene. Evolus is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Evolus $297.18M 1.54 -$51.64M -$0.67 N/A

Is ENGN or EOLS more profitable?

enGene has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Evolus -14.39% N/A -19.03%

Is BNTC or ENGN more profitable?

Benitec Biopharma's return on equity of -34.82% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% enGene N/A -56.06% -45.64%

Does the media refer more to ENGN or AUTL?

In the previous week, enGene had 10 more articles in the media than Autolus Therapeutics. MarketBeat recorded 13 mentions for enGene and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.63 beat enGene's score of 0.21 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

enGene (ENGN) Competitors

$1.73 -0.05 (-2.81%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$1.77 +0.04 (+2.31%)

As of 04:04 AM Eastern

Compare

ENGN vs. DTSS, CTNM, EOLS, BNTC, and AUTL

Should you buy enGene stock or one of its competitors? MarketBeat compares enGene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with enGene include Datasea (DTSS), Contineum Therapeutics (CTNM), Evolus (EOLS), Benitec Biopharma (BNTC), and Autolus Therapeutics (AUTL).

How does enGene compare to Datasea?

enGene (NASDAQ:ENGN) and Datasea (NASDAQ:DTSS) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

enGene has a net margin of 0.00% compared to Datasea's net margin of -4.80%. enGene's return on equity of -56.06% beat Datasea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Datasea	-4.80%	-88.98%	-37.33%

enGene presently has a consensus target price of $11.05, indicating a potential upside of 538.47%. Given enGene's stronger consensus rating and higher possible upside, research analysts clearly believe enGene is more favorable than Datasea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Datasea	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

64.2% of enGene shares are held by institutional investors. Comparatively, 82.1% of Datasea shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 50.7% of Datasea shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, enGene had 11 more articles in the media than Datasea. MarketBeat recorded 13 mentions for enGene and 2 mentions for Datasea. Datasea's average media sentiment score of 0.43 beat enGene's score of 0.21 indicating that Datasea is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Datasea	Neutral

enGene has a beta of -0.3, indicating that its stock price is 130% less volatile than the broader market. Comparatively, Datasea has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Datasea has higher revenue and earnings than enGene. Datasea is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Datasea	$71.62M	0.11	-$5.09M	-$0.32	N/A

Summary

Datasea beats enGene on 8 of the 15 factors compared between the two stocks.

How does enGene compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

64.2% of enGene shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Contineum Therapeutics' return on equity of -27.09% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
enGene	N/A	-56.06%	-45.64%

Contineum Therapeutics currently has a consensus price target of $20.00, suggesting a potential upside of 22.47%. enGene has a consensus price target of $11.05, suggesting a potential upside of 538.47%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Contineum Therapeutics has higher revenue and earnings than enGene. Contineum Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	12.21	-$59.98M	-$1.95	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

In the previous week, enGene had 9 more articles in the media than Contineum Therapeutics. MarketBeat recorded 13 mentions for enGene and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.62 beat enGene's score of 0.21 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Contineum Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, enGene has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market.

Summary

Contineum Therapeutics beats enGene on 8 of the 14 factors compared between the two stocks.

How does enGene compare to Evolus?

enGene (NASDAQ:ENGN) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

enGene has a beta of -0.3, meaning that its share price is 130% less volatile than the broader market. Comparatively, Evolus has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

enGene presently has a consensus target price of $11.05, indicating a potential upside of 538.47%. Evolus has a consensus target price of $16.00, indicating a potential upside of 130.55%. Given enGene's higher possible upside, equities research analysts plainly believe enGene is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, enGene had 12 more articles in the media than Evolus. MarketBeat recorded 13 mentions for enGene and 1 mentions for Evolus. Evolus' average media sentiment score of 1.89 beat enGene's score of 0.21 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Evolus	Very Positive

Evolus has higher revenue and earnings than enGene. Evolus is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Evolus	$297.18M	1.54	-$51.64M	-$0.67	N/A

64.2% of enGene shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

enGene has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Evolus	-14.39%	N/A	-19.03%

Summary

Evolus beats enGene on 9 of the 14 factors compared between the two stocks.

How does enGene compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Benitec Biopharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, enGene has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market.

Benitec Biopharma's return on equity of -34.82% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
enGene	N/A	-56.06%	-45.64%

In the previous week, enGene had 12 more articles in the media than Benitec Biopharma. MarketBeat recorded 13 mentions for enGene and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.87 beat enGene's score of 0.21 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Very Positive
enGene	Neutral

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Benitec Biopharma presently has a consensus price target of $27.00, indicating a potential upside of 101.79%. enGene has a consensus price target of $11.05, indicating a potential upside of 538.47%. Given enGene's higher possible upside, analysts clearly believe enGene is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Benitec Biopharma has higher revenue and earnings than enGene. Benitec Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	5,745.04	-$37.92M	-$1.14	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

Summary

Benitec Biopharma beats enGene on 9 of the 14 factors compared between the two stocks.

How does enGene compare to Autolus Therapeutics?

enGene (NASDAQ:ENGN) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

enGene presently has a consensus target price of $11.05, indicating a potential upside of 538.47%. Autolus Therapeutics has a consensus target price of $8.75, indicating a potential upside of 446.88%. Given enGene's higher possible upside, equities analysts plainly believe enGene is more favorable than Autolus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

enGene has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. enGene's return on equity of -56.06% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

enGene has a beta of -0.3, suggesting that its share price is 130% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

64.2% of enGene shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

enGene has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Autolus Therapeutics	$75.39M	5.65	-$287.53M	-$1.09	N/A

In the previous week, enGene had 10 more articles in the media than Autolus Therapeutics. MarketBeat recorded 13 mentions for enGene and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.63 beat enGene's score of 0.21 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Autolus Therapeutics beats enGene on 9 of the 16 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$119.23M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.80	20.90	27.25	24.87
Price / Sales	N/A	341.80	543.53	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.45	8.75	10.93	6.54
Net Income	-$117.30M	$23.81M	$3.57B	$336.70M
7 Day Performance	-1.14%	3.60%	2.31%	2.88%
1 Month Performance	-2.81%	3.72%	1.39%	0.64%
1 Year Performance	-52.21%	68.80%	36.73%	31.34%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	4.1114 of 5 stars	$1.73 -2.8%	$11.05 +538.5%	-52.5%	$119.23M	N/A	N/A	31
DTSS Datasea	0.585 of 5 stars	$0.79 +3.9%	N/A	-60.8%	$8.25M	$56.89M	N/A	120
CTNM Contineum Therapeutics	1.9226 of 5 stars	$11.91 +2.5%	$20.00 +67.9%	+311.3%	$445.27M	N/A	N/A	31	News Coverage
EOLS Evolus	2.7357 of 5 stars	$6.74 +2.3%	$16.00 +137.4%	-24.6%	$443.86M	$301.79M	N/A	170
BNTC Benitec Biopharma	1.9517 of 5 stars	$12.88 +4.7%	$27.00 +109.6%	+14.4%	$442.48M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors

ENGN vs. DTSS, CTNM, EOLS, BNTC, and AUTL

How does enGene compare to Datasea?

Summary

How does enGene compare to Contineum Therapeutics?

Summary

How does enGene compare to Evolus?

Summary

How does enGene compare to Benitec Biopharma?

Summary

How does enGene compare to Autolus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enGene (ENGN) Competitors

ENGN vs. DTSS, CTNM, EOLS, BNTC, and AUTL

How does enGene compare to Datasea?

Is ENGN or DTSS more profitable?

Do analysts rate ENGN or DTSS?

Do insiders and institutionals have more ownership in ENGN or DTSS?

Does the media refer more to ENGN or DTSS?

Which has more volatility & risk, ENGN or DTSS?

Which has stronger valuation & earnings, ENGN or DTSS?

Summary

How does enGene compare to Contineum Therapeutics?

Do insiders & institutionals hold more shares of CTNM or ENGN?

Is CTNM or ENGN more profitable?

Do analysts rate CTNM or ENGN?

Which has higher earnings & valuation, CTNM or ENGN?

Does the media refer more to CTNM or ENGN?

Which has more risk & volatility, CTNM or ENGN?

Summary

How does enGene compare to Evolus?

Which has more risk and volatility, ENGN or EOLS?

Do analysts prefer ENGN or EOLS?

Does the media favor ENGN or EOLS?

Which has higher valuation and earnings, ENGN or EOLS?

Do insiders & institutionals have more ownership in ENGN or EOLS?

Is ENGN or EOLS more profitable?

Summary

How does enGene compare to Benitec Biopharma?

Which has more volatility & risk, BNTC or ENGN?

Is BNTC or ENGN more profitable?

Does the media prefer BNTC or ENGN?

Do insiders and institutionals have more ownership in BNTC or ENGN?

Do analysts rate BNTC or ENGN?

Which has higher earnings and valuation, BNTC or ENGN?

Summary

How does enGene compare to Autolus Therapeutics?

Do analysts rate ENGN or AUTL?

Is ENGN or AUTL more profitable?

Which has more volatility and risk, ENGN or AUTL?

Do insiders & institutionals believe in ENGN or AUTL?

Which has better valuation and earnings, ENGN or AUTL?

Does the media refer more to ENGN or AUTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools